Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.48 |
| ▸ | VEGFA | P15692 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814820 | 0.81 | FAAH (0.46) | HRH3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4815663 | 0.80 | HRH3 (0.48) | HRH3 | |
| SCHEMBL28699382 | 0.79 | VEGFA (0.47) | GPR119IDO1TDO2IDO2VEGFA | |
| SCHEMBL4815397 | 0.79 | LMNA (0.49) | HRH3CA2 | |
| SCHEMBL27539906 | 0.78 | VEGFA (0.53) | IDO1TDO2IDO2VEGFAEGLN1 | |
| SCHEMBL4894879 | 0.78 | ALDH1A1 (0.49) | HRH3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30038994 | 0.77 | VEGFA (0.49) | GPR119IDO1TDO2IDO2VEGFA | |
| SCHEMBL28449818 | 0.77 | VEGFA (0.49) | GPR119IDO1TDO2IDO2VEGFA | |
| SCHEMBL5030322 | 0.77 | KDM1A (0.57) | VEGFAEGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3596539 | 0.77 | FAAH (0.56) | VEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | GPR119 2143/4885IDO1 1726/4885TDO2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.